FY2024 EPS Estimates for Moderna Cut by Analyst

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Brookline Capital Management dropped their FY2024 earnings estimates for shares of Moderna in a report released on Monday, January 13th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($9.15) per share for the year, down from their previous estimate of ($9.12). The consensus estimate for Moderna's current full-year earnings is ($9.30) per share. Brookline Capital Management also issued estimates for Moderna's Q4 2024 earnings at ($2.85) EPS, FY2025 earnings at ($8.56) EPS, FY2026 earnings at ($2.00) EPS, FY2027 earnings at $1.30 EPS and FY2028 earnings at $5.31 EPS.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley dropped their target price on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a report on Wednesday. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Hsbc Global Res raised shares of Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Wolfe Research assumed coverage on shares of Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 target price on the stock. Finally, Berenberg Bank lifted their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday. Four equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $75.58.

Moderna Stock Performance

NASDAQ:MRNA traded down $1.01 during mid-day trading on Thursday, hitting $33.76. 7,323,516 shares of the stock were exchanged, compared to its average volume of 12,449,448. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm's 50-day simple moving average is $41.11 and its 200 day simple moving average is $67.32. Moderna has a fifty-two week low of $31.94 and a fifty-two week high of $170.47. The stock has a market capitalization of $12.99 billion, a price-to-earnings ratio of -5.80 and a beta of 1.60.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.39) earnings per share.

Institutional Investors Weigh In On Moderna

Hedge funds have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the second quarter valued at about $26,000. Itau Unibanco Holding S.A. bought a new position in Moderna in the 2nd quarter valued at approximately $75,000. Blue Trust Inc. boosted its position in Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock worth $49,000 after buying an additional 574 shares during the period. Larson Financial Group LLC boosted its position in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after buying an additional 317 shares during the period. Finally, Rakuten Securities Inc. grew its holdings in Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock worth $63,000 after acquiring an additional 778 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. Insiders own 15.20% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.